



Xellia Pharmaceuticals appoints Hanne Junggreen as Corporate Vice President of Global Quality

Copenhagen, Denmark, 18 January 2023 - Xellia Pharmaceuticals ('Xellia'), a global leader in the manufacturing of specialty anti-infective treatments and critical care therapies has appointed Hanne Junggreen as Corporate Vice President of Global Quality from 1 January 2023.

Hanne has been with Xellia for more than 25 years and has contributed greatly to Xellia through her multi-faceted roles in the organization over the years. Hanne has held various senior leadership positions since joining Xellia both within Quality and Production across Active Pharmaceutical Ingredient and Aseptic Drug Product manufacturing. Joining Xellia's Leadership Team, Hanne will be based at the Company's headquarters in Copenhagen, Denmark.

Carl-Åke Carlsson, CEO and President at Xellia Pharmaceuticals, commented:

"We are very pleased to appoint and welcome Hanne Junggreen as our new Corporate Vice President, Global Quality. Hanne will be a key asset to the team, bringing with her extensive managerial experience within Quality and Manufacturing from key senior leadership roles within the company."

Hanne graduated as a Chemical Engineer from the University of Southern Denmark.

- Ends -

For more information, please contact:

Xellia Pharmaceuticals

Carl-Åke Carlsson, CEO
+45 32 64 55 00

Instinctif Partners (International media relations)

Melanie Toyne-Sewell / Rozi Morris
+44 (0) 20 7457 2020
xellia@instinctif.com

About Xellia Pharmaceuticals

Xellia Pharmaceuticals is a specialty pharmaceutical company and a global leader in providing anti-infective treatments and other critical care therapies for serious and often life-threatening conditions. Xellia has an extensive history in developing, manufacturing, and commercializing anti-infective products, including Active Pharmaceutical Ingredients (APIs) as well as Finished Dosage Forms, where the majority are injectable drug products.

As an organization, Xellia is committed to providing security and consistency of supply of critical care therapies. Through a global vertically integrated supply chain, the Company continuously works to improve supply security through multiple sources of in-house production of its APIs and drug products, and in conjunction through working alongside Xellia's R&D centers of excellence. Through innovation and with the patient in focus, Xellia is building a pipeline of value-added critical care therapies which aim to enhance patient care by providing convenience and ease of use for healthcare professionals.

Headquartered in Copenhagen, Denmark, Xellia has a global footprint with R&D, manufacturing and commercial operations across Europe, Asia, the Middle East and North America. Xellia Pharmaceuticals is wholly owned by Novo Holdings A/S and employs a dedicated team of more than 1,800 people.